A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM
Purpose
Prospective, multi-center, double blind, randomized, sham-controlled study to evaluate neuromodulation in patient with chronic migraine. The study hypothesis to be tested is the mean reduction in mean monthly headache days between patients in treatment versus sham.
Condition
- Headache Migraine Chronic
Eligibility
- Eligible Ages
- Over 22 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- ≥ 22 years of age. 2. Have migraine onset at ≤ 50 years of age. 3. Have a history of migraine for ≥ 12 months prior to screening. 4. Have 15 - 26 headache days/month, among which ≥ 8 days has the features of probable migraine, and minimum of 2 headache-free days/month during the 28-day screening period. 5. Fulfill the criteria for chronic migraine (CM) during the 28-day screening period. 6. Have a diagnosis of refractory chronic migraine (RCM), who have inadequate response or no access to, or are intolerant, unwilling, or contraindicated to Onabotulinum toxin A (Botox) therapy, and One of the medications that belong to Calcitonin Gene Related Peptide Monoclonal antibodies (CGRP) therapy or CGRP antagonist therapy. 7. Maintain a stable use of preventive(s) migraine medication for ≥ 3 months before screening. Subjects receiving OnabotunlinumtoxinA must stop therapy ≥ 3 months prior to screening visit. 8. Demonstrate ≥ 80% compliance with the headache diary during the screening period by entering headache data on a minimum of 22 out of 28 days. 9. Be willing and able to comply with all study procedures and return to the clinic for the follow-up evaluation, as specified in this protocol. 10. Be able to give voluntary, written informed consent to participate in this study.
Exclusion Criteria
- Type of headache or migraine other than RCM including the following: 1. Post-traumatic headache (e.g., battlefield, accidents, etc.). 2. Regular intake of opioids (including codeine) of ≥ 8 days in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis. 3. Regular intake of Barbiturates for ≥ 5 days/month in the past 3 months and during the 28-day screening/baseline phase and cannot be accounted for by another diagnosis. 4. Report experiencing unremitting, continuous headaches with no relief. 5. Have new daily persistent headache (NDPH) defined by iCHD-3 as persistent headache, daily from its onset, which is clearly remembered. The pain lacks characteristic features and may be migraine-like or tension-type like or have elements of both with a CM subtype. 2. History of treatments that could confound the results of the study 1. Previously implanted neurostimulator to stimulate the greater occipital and/or supraorbital nerves to treat headache. 2. Have received onabotulinumtoxinA (Botox) for any other medical or cosmetic reasons requiring injections in the head, face, or neck within 3 months prior to screening. 3. Have had any cervical radiofrequency ablation within 12 months. 4. Subjects with recent brain or facial trauma occurring less than 3 months prior to the Baseline Visit. 5. Subjects that may have received sequential multi-day in-patient parenteral infusion for the treatment of a migraine condition (e.g., status migrainosus) within the previous 2 weeks of the initiation of diary screening phase. 6. Subjects with any metallic implant located in the head including CSF shunt and surgical clip above the shoulder line (excluding dental implants). 7. Subject has other implanted electrical stimulation device(s) including: 1. Cardiac pacemakers or defibrillators 2. Cochlear implant 3. Intrathecal pumps 4. Spinal cord stimulator 5. Other stimulator device 8. Use of nerve blocks, acupuncture, neurostimulation and/or transcranial magnetic stimulation) for migraine within 3 months prior to screening and after receiving implant system. 9. Any pre-existing or requirement of emergent surgery/procedure that may interfere or confound the results of the study. 10. Any known requirement for an MRI scan subsequent to implant of the neurostimulator. 11. Current or history of following comorbidities: 1. Clinically significant psychiatric illnesses, including suicide attempt, or suicidal ideation with a specific plan in the past 2 years. 2. Cancer in the past 5 years, except for appropriately treated nonmelanoma skin carcinoma. 3. Have a current diagnosis or condition that presents excess risk for performing the procedure, as determined clinically by the Investigator. 4. Substance use disorder of at least moderate severe for substances such as; alcohol, recreational marijuana, or illicit drugs during the past 2 years. 12. Unable to participate or successfully complete the study, in the opinion of the investigator. 13. Anatomy not suitable for placement of the study device. 14. Are currently a study center or Sponsor employee who is directly involved in the study or the relative of such an employee. 15. Pregnant or lactating female or planning a pregnancy during participation in the study. 16. Patient with life expectancy of less than 1.5 years. 17. Currently participating in or planning to participate in other investigational drug or device studies that may interfere or confound the results of the study.
Study Design
- Phase
- N/A
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Prevention
- Masking
- Double (Participant, Investigator)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Active Comparator High Dose |
|
|
|
Sham Comparator Low Dose |
|
Recruiting Locations
Mayo Clinic Arizona
Scottsdale 5313457, Arizona 5551752 85259
Scottsdale 5313457, Arizona 5551752 85259
University of Arkansas for Medical Sciences
Little Rock 4119403, Arkansas 4099753 72205
Little Rock 4119403, Arkansas 4099753 72205
UC San Diego Health
La Jolla 5363943, California 5332921 92037
La Jolla 5363943, California 5332921 92037
Neurovations
Napa 5376095, California 5332921 94558
Napa 5376095, California 5332921 94558
Barolat Neuroscience
Denver 5419384, Colorado 5417618 80218
Denver 5419384, Colorado 5417618 80218
Ayer Neuroscience Institute Headache Center
Hartford 4835797, Connecticut 4831725 06106
Hartford 4835797, Connecticut 4831725 06106
Mayo Clinic Florida
Jacksonville 4160021, Florida 4155751 32224
Jacksonville 4160021, Florida 4155751 32224
Vista Clinical Research and Summit Spine & Joint
Newnan 4212684, Georgia 4197000 30265
Newnan 4212684, Georgia 4197000 30265
iSpine Clinics
Chaska 5020938, Minnesota 5037779 55318
Chaska 5020938, Minnesota 5037779 55318
Mayo Clinic Rochester
Rochester 5043473, Minnesota 5037779 55905
Rochester 5043473, Minnesota 5037779 55905
Dent Neurologic Institute
Amherst 5107129, New York 5128638 14226
Amherst 5107129, New York 5128638 14226
Northwell Health Physician Partners
New York 5128581, New York 5128638 10019
New York 5128581, New York 5128638 10019
Queen City Clinical Research
Charlotte 4460243, North Carolina 4482348 28211
Charlotte 4460243, North Carolina 4482348 28211
The Center for Clinical Research
Winston-Salem 4499612, North Carolina 4482348 27103
Winston-Salem 4499612, North Carolina 4482348 27103
Argires Marotti Neurological Associates
Lancaster 5197079, Pennsylvania 6254927 17601
Lancaster 5197079, Pennsylvania 6254927 17601
Jefferson Headache Center
Philadelphia 4560349, Pennsylvania 6254927 19107
Philadelphia 4560349, Pennsylvania 6254927 19107
Texas Neurology
Dallas 4684888, Texas 4736286 75206
Dallas 4684888, Texas 4736286 75206
More Details
- NCT ID
- NCT06167655
- Status
- Recruiting
- Sponsor
- ShiraTronics